Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia

This two-part observational trial (n=50) will evaluate the safety and efficacy of intravenous ketamine infusions (1.5–2 mg/kg over 3–4 hours) in reducing pain among patients diagnosed with fibromyalgia.

Conducted by the Wilderman Medical Clinic in Ontario, Canada, this study includes both retrospective and prospective arms. The retrospective component reviews medical records from fibromyalgia patients who previously received at least four ketamine infusions, assessing their short- and long-term pain relief. The prospective component involves patients who have undergone at least three prior infusions to optimise dosing; these participants will receive one additional infusion and be assessed before, shortly after, and at follow-up for pain reduction, safety, and tolerability.

The study seeks to expand on limited existing research by following the infusion duration and dosing recommendations of established clinical guidelines. It will also explore whether patient characteristics (such as mood or dissociative symptoms) influence treatment response. The aim is to generate data that can inform personalised approaches to ketamine treatment for chronic pain in fibromyalgia.

Topic Pain Safety Fibromyalgia
Compound Ketamine
Country Canada
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.